{"id":"W2047634988","doi":"10.1111/j.1365-2141.2009.07836.x","title":"Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non‐Hodgkin lymphoma","year":2009,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"National Center for Research Resources; National Cancer Institute; Case Comprehensive Cancer Center, Case Western Reserve University","keywords":"Bortezomib; Mantle cell lymphoma; Fludarabine; Medicine; Rituximab; Internal medicine; Chronic lymphocytic leukemia; Follicular lymphoma; Lymphoma; Regimen; Oncology; Aggressive lymphoma; Gastroenterology; Multiple myeloma; Chemotherapy; Leukemia; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001776276,0.001298152,0.002071269,0.0003413852,0.0003827246,0.0008985342,0.001029631,0.001515016,0.002678796],"category_scores_gemma":[0.001040041,0.0004924064,0.0009050291,0.000370539,0.0008861767,0.0005864548,0.000420118,0.002483237,0.0006297793],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001023323,"about_ca_system_score_gemma":0.001446346,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001036964,"about_ca_topic_score_gemma":0.002222986,"domain_scores_codex":[0.9994549,0.0003276505,0.00002851669,0.00005346753,0.00003396565,0.0001015643],"domain_scores_gemma":[0.9991946,0.0001512816,0.0001128806,0.00004040708,0.00003339351,0.0004675363],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8179771,0.03532742,0.006299581,0.0008173286,0.001125043,0.0007156506,0.0003545551,0.002371808,0.02688327,0.0003776453,0.004248441,0.1035022],"study_design_scores_gemma":[0.7157748,0.272788,0.00582691,0.00004074481,0.0002757846,0.000381409,0.00005277127,0.0007922001,0.001499815,0.0001619959,0.002387168,0.00001843757],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905595,0.003827126,0.0004239556,0.0006044238,0.0001608001,0.002195884,0.0003504454,0.00008329128,0.001794504],"genre_scores_gemma":[0.9875586,0.002347568,0.001556033,0.001252258,0.000217531,0.003214943,0.001327105,0.00002092132,0.002505113],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002678796,"threshold_uncertainty_score":0.00939399,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01446230266339019,"score_gpt":0.315413557958335,"score_spread":0.3009512552949448,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}